Crystal Watson

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 8

Top Topics

Patient Reported Outcomes

Epstein Barr Virus

Ejection Fraction

Top Venues

Journal of medical economics

Neurology and therapy

Journal of drug assessment

Oncology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Crystal Watson, Dhanalakshmi Thirumalai, Arie Barlev, Eddie Jones, Sasha Bogdanovich, Kiren Kresa-Reahl
Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021. Neurology and therapy (2023)
Crystal Watson, Hemanth Gadikota, Arie Barlev, Rachel Beckerman
A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen. Journal of drug assessment 11 (1) (2022)
Crystal Watson, Kayla Scippa, Arie Barlev, Kiren Kresa-Reahl, Jason C Cole
Results from Patient Interviews on Fatigue in Progressive Multiple Sclerosis and Evaluation of Fatigue Patient-Reported Outcome (PRO) Instruments. Neurology and therapy 11 (2) (2022)
Christopher N Graham, Crystal Watson, Arie Barlev, Matthew D Stevenson, Vikas R Dharnidharka
Mean lifetime survival estimates following solid organ transplantation in the US and UK. Journal of medical economics 25 (1) (2022)
Allyson Hart, Yoon Son Ahn, Crystal Watson, Melissa Skeans, Arie Barlev, Bryn Thompson, Vikas R Dharnidharka
Cost burden of post-transplant lymphoproliferative disease following kidney transplants in Medicare-eligible patients by survival status. Journal of medical economics 24 (1) (2021)
Crystal Watson, Arie Barlev, Jason C Cole, Bhumi Trivedi
Qualitative Findings on the Impact of Disease in Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Patients, as Measured by EQ-5D, SF-36, and the FACT-LYM. Oncology and therapy 8 (2) (2020)
Crystal Watson, Hairong Xu, Princic Nicole, Ila Sruti, Arie Barlev
Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants. Journal of medical economics 23 (10) (2020)
Crystal Watson, Arie Barlev, Jodie Worrall, Steve Duff, Rachel Beckerman
Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients. Journal of drug assessment 10 (1) (2020)